Lupin Limited (BOM: 500257)

Market Cap	1.01T
Revenue (ttm)	207.97B
Net Income (ttm)	22.64B
Shares Out	456.14M
EPS (ttm)	49.49
PE Ratio	44.91
Forward PE	36.06
Dividend	8.00 (0.36%)
Ex-Dividend Date	Jul 16, 2024

Volume	48
Open	2,223.60
Previous Close	2,216.95
Day's Range	2,214.00 - 2,251.30
52-Week Range	1,091.80 - 2,312.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nerv...

• Industry: Pharmaceutical Preparations
• Founded: 1968
• Employees: 19,210
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500257

Financial Performance

In 2023, Lupin's revenue was 200.11 billion, an increase of 20.25% compared to the previous year's 166.42 billion. Earnings were 19.14 billion, an increase of 345.15%.